These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16234778)

  • 1. [The place of aldosterone receptor blockers in the treatment of chronic heart failure].
    Kardiologiia; 2005; 45(10):76-81. PubMed ID: 16234778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
    Kalidindi SR; Tang WH; Francis GS
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of aldosterone receptor antagonists in the management of heart failure: an update.
    Nagarajan V; Chamsi-Pasha M; Tang WH
    Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aldosterone antagonist therapy for chronic heart failure].
    Yamamoto T; Yano M
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):262-9. PubMed ID: 15768590
    [No Abstract]   [Full Text] [Related]  

  • 7. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
    Fügedi K
    Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA).
    Coats AJ
    Int J Cardiol; 2001 Aug; 80(1):1-4. PubMed ID: 11532539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
    Kolloch R; Offers E
    MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
    Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
    Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
    Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
    Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
    Karagiannis A; Athyros VG; Mikhailidis DP
    Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
    [No Abstract]   [Full Text] [Related]  

  • 19. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
    Nappi JM; Sieg A
    Vasc Health Risk Manag; 2011; 7():353-63. PubMed ID: 21731887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.